RYAN THOMAS F JR
Known title: DirectorCIK: 0001263366
Associated companies
Transaction History
| RGEN | ▲ Buy | Option Exercise | 1,000 | $39K | 3/1/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,000 | $198K | 3/1/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,000 | $198K | 3/1/2022 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,000 | $288K | 11/4/2021 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 1,285 | $165K | 11/2/2021 | View on chart |
| RGEN | ▼ Sell | Open Market | 1,285 | $388K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.